Kratom Seller Advocates Access Amid FDA Guidelines Discussion

During a recent meeting of the Louisiana House Criminal Justice Committee on May 14, 2025, discussions centered around the controversial herbal supplement kratom, highlighting its regulatory status and implications for public health.

A key point of contention arose regarding the lack of FDA approval for kratom, with committee members questioning its classification and safety guidelines. One participant emphasized that while kratom is not FDA-approved, it is still regulated under the Dietary Supplement Health and Education Act of 1994, which allows the FDA to oversee dietary products sold in stores. This distinction sparked a debate about the transparency of kratom manufacturers and the information available to policymakers.

The conversation also touched on the market dynamics surrounding kratom, particularly its availability in vape shops rather than mainstream retailers like GNC. A vape shop owner testified that kratom accounts for 20 to 30% of his sales, indicating a significant consumer interest despite its controversial status. He noted that the product has been "demonized," which may contribute to its limited presence in larger retail chains.

Concerns were raised about the packaging of kratom products, with committee members questioning whether it resembles candy, potentially appealing to children. The vape shop owner defended his practices, stating he adheres to guidelines from the American Kratom Association and is vigilant about product safety.

The meeting concluded with a discussion on the potential for stricter regulations, including making kratom available only by prescription, akin to medical marijuana. The shop owner opposed this idea, arguing that many individuals lack access to medical professionals and should have the freedom to choose their health options.

As the committee continues to evaluate kratom's status, the implications of their decisions could significantly impact both consumer access and public health in Louisiana. The ongoing dialogue reflects a broader national conversation about the regulation of herbal supplements and their place in the marketplace.